Stephenson Harwood advises on £162 million IPO for Shield Therapeutics plc
Stephenson Harwood LLP has advised Shield Therapeutics plc (“Shield”) on its £162 million AIM IPO.
The IPO involved the placing and subscription of £32.5 million of new ordinary shares, and the issue of warrants to subscribe for ordinary shares. If these warrants were exercised in full, they would generate an additional £17.5 million of gross proceeds for Shield. Shield is seeking admission to trading on AIM, a market operated by the London Stock Exchange. Admission to AIM is expected to take place tomorrow, 26 February 2016.